Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Fibroblast-like synoviocytes preferentially induce terminal differentiation of IgD + memory B cells instead of naïve B cells
  • +3
  • Dennis Bleck,
  • Klara Loacker-Schöch,
  • Tim Classen,
  • Joachim Jose,
  • Matthias Schneider,
  • Georg Pongratz
Dennis Bleck
Heinrich-Heine-Universitat Dusseldorf Medizinische Fakultat

Corresponding Author:[email protected]

Author Profile
Klara Loacker-Schöch
Heinrich-Heine-Universitat Dusseldorf Medizinische Fakultat
Author Profile
Tim Classen
St Elisabeth-Hospital Meerbusch-Lank
Author Profile
Joachim Jose
Westfalische Wilhelms-Universitat Munster
Author Profile
Matthias Schneider
Heinrich-Heine-Universitat Dusseldorf Medizinische Fakultat
Author Profile
Georg Pongratz
Heinrich-Heine-Universitat Dusseldorf Medizinische Fakultat
Author Profile

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease driven by highly active autoantibody producing B cells. These B cells can be supported within ectopic germinal centers found in afflicted joints. Fibroblast like synoviocytes (FLS) present in inflamed joints support B cell survival, activation and differentiation. CD27 + memory B cells and naïve B cells show very distinct reactions to activation, particularly by CD40 ligand (CD40L). We show that FLS dependent activation of human B cells is dependent on interleukin 6 (IL-6) and CD40L. FLS have been shown to activate naïve as well as memory B cells. If the activatory potential of FLS is different for naïve and memory B cells had not yet been investigated. Our results suggest that FLS-induced activation of B cells is dependent on IL-6 and CD40L. While FLS are capable of inducing differentiation, isotype switching and antibody production in memory B cells, FLS capability to activate naive B cells is significantly lower.
05 Jul 2023Submitted to Immunology
06 Jul 2023Review(s) Completed, Editorial Evaluation Pending
06 Jul 2023Submission Checks Completed
06 Jul 2023Assigned to Editor
12 Jul 2023Reviewer(s) Assigned
13 Jun 2024Editorial Decision: Revise Minor
02 Jul 20241st Revision Received
03 Jul 2024Review(s) Completed, Editorial Evaluation Pending
10 Jul 2024Editorial Decision: Accept